{
  "over_18_initiation_no_weightloss_agent_bmi_over_27": {
    "header": "Verify Prescriber and Patient Documentation",
    "items": [
      {
        "label": "Documented baseline body mass index (BMI) ≥ 27 kg/m^2.",
        "validation": "An initial BMI of less than 27 kg/m^2 is unlikely to be approved."
      },
      {
        "label": "Document the patient has not tried a targeted weight loss agent in the past 12 months.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      }
    ]
  },
  "over_18_initiation_no_weightloss_agent_bmi_over_30": {
    "header": "Verify Prescriber and Patient Documentation",
    "items": [
      {
        "label": "Documented baseline body mass index (BMI) ≥ 30 kg/m^2.",
        "validation": "An initial BMI of less than 30 kg/m^2 is unlikely to be approved."
      },
      {
        "label": "Document the patient has not tried a targeted weight loss agent in the past 12 months.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      }
    ]
  },
  "over_18_initiation_with_weightloss_agent_bmi_over_30": {
    "header": "Verify Prescriber and Patient Documentation",
    "items": [
      {
        "label": "Documented baseline body mass index (BMI) ≥ 30 kg/m^2.",
        "validation": "An initial BMI of less than 30 kg/m^2 is unlikely to be approved."
      },
      {
        "label": "Document the patient has tried a targeted weight loss agent for a previous course of therapy in the past 12 months AND the prescriber anticipates success with repeating therapy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      }
    ]
  },
  "over_18_initiation_with_weightloss_agent_bmi_over_27": {
    "header": "Verify Prescriber and Patient Documentation",
    "items": [
      {
        "label": "Documented baseline body mass index (BMI) ≥ 27 kg/m^2.",
        "validation": "An initial BMI of less than 27 kg/m^2 is unlikely to be approved."
      },
      {
        "label": "Document the patient has tried a targeted weight loss agent for a previous course of therapy in the past 12 months AND the prescriber anticipates success with repeating therapy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      }
    ]
  },
  "over_18_initiation_south_asian_no_weightloss_agent": {
    "header": "Verify Prescriber and Patient Documentation",
    "items": [
      {
        "label": "Documented baseline body mass index (BMI) ≥ 25 kg/m^2.",
        "validation": "An initial BMI of less than 25 kg/m^2 is unlikely to be approved."
      },
      {
        "label": "Document the patient has not tried a targeted weight loss agent in the past 12 months.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      }
    ]
  },
  "over_18_initiation_south_asian_with_weightloss_agent": {
    "header": "Verify Prescriber and Patient Documentation",
    "items": [
      {
        "label": "Documented baseline body mass index (BMI) ≥ 25 kg/m^2.",
        "validation": "An initial BMI of less than 25 kg/m^2 is unlikely to be approved."
      },
      {
        "label": "Document the patient has tried a targeted weight loss agent for a previous course of therapy in the past 12 months AND the prescriber anticipates success with repeating therapy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      }
    ]
  },
  "below_18_initiation_no_weightloss_agent_bmi_over_85": {
    "header": "Verify Prescriber and Patient Documentation",
    "items": [
      {
        "label": "Document the patient has a diagnosis of obesity, confirmed by a body mass index (BMI) ≥ 85th percentile for age and gender.",
        "validation": "Wegovy is unlikely to get approved for BMI below 85th percentile."
      },
      {
        "label": "Document the patient has not tried a targeted weight loss agent in the past 12 months.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      }
    ]
  },
  "below_18_initiation_no_weightloss_agent_bmi_over_95": {
    "header": "Verify Prescriber and Patient Documentation",
    "items": [
      {
        "label": "Document the patient has a diagnosis of obesity, confirmed by a body mass index (BMI) ≥ 95th percentile for age and gender.",
        "validation": "Wegovy is unlikely to get approved for BMI below 95th percentile."
      },
      {
        "label": "Document the patient has not tried a targeted weight loss agent in the past 12 months.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      }
    ]
  },
  "below_18_initiation_with_weightloss_agent_bmi_over_85": {
    "header": "Verify Prescriber and Patient Documentation",
    "items": [
      {
        "label": "Document the patient has a diagnosis of obesity, confirmed by a body mass index (BMI) ≥ 85th percentile for age and gender.",
        "validation": "Wegovy is unlikely to get approved for BMI below 85th percentile."
      },
      {
        "label": "Document the patient has tried a targeted weight loss agent for a previous course of therapy in the past 12 months AND the prescriber anticipates success with repeating therapy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      }
    ]
  },
  "below_18_initiation_with_weightloss_agent_bmi_over_95": {
    "header": "Verify Prescriber and Patient Documentation",
    "items": [
      {
        "label": "Document the patient has a diagnosis of obesity, confirmed by a body mass index (BMI) ≥ 95th percentile for age and gender.",
        "validation": "Wegovy is unlikely to get approved for BMI below 95th percentile."
      },
      {
        "label": "Document the patient has tried a targeted weight loss agent for a previous course of therapy in the past 12 months AND the prescriber anticipates success with repeating therapy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      }
    ]
  },
  "over_18_continuation_under_52_weeks": {
    "header": "Verify Prescriber and Patient Documentation",
    "items": [
      {
        "label": "Document patient has recieved less than 52 weeks of therapy on the 2.4mg dose.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      }
    ]
  },
  "over_18_continuation_over_52weeks": {
    "header": "Verify Prescriber and Patient Documentation",
    "items": [
      {
        "label": "Document patient has achieved and is maintained a reduction of BMI of at least 5% from baseline.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission.."
      },
      {
        "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      }
    ]
  },
  "below_18_continuation_over_52weeks": {
    "header": "Verify Prescriber and Patient Documentation",
    "items": [
      {
        "label": "Document patient has achieved and is maintained a reduction of BMI of at least 5% from baseline.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document current BMI is greater than 85th percentile for age and gender.",
        "validation": "A current BMI of less than 85th is unlikely to be approved."
      },
      {
        "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weight loss medication.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      }
    ]
  },
  "below_18_continuation_under_52weeks": {
    "header": "Verify Prescriber and Patient Documentation",
    "items": [
      {
        "label": "Document patient has received less than 52 weeks of therapy on the 1.7 or 2.4mg dose.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document current BMI is greater than 85th percentile for age and gender.",
        "validation": "A current BMI of less than 85th percentile is unlikely to be approved."
      },
      {
        "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weight loss medication.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      },
      {
        "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
        "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
      }
    ]
  }
}
